Montag, 19. April 2021
Navigation öffnen

First-in-Human Study of the GDF-15 Neutralizing Antibody CTL-002 in Patients With Advanced Cancer (GDFATHER)



Dezember 2020

Letztes Update:



Erwachsene (18+)

Phase 1

CatalYm GmbH



Eugen Leo, MD, PhD, MBA
Study Director
CatylYm GmbH


(3 von 6)

Universitätsklinikum Essen, Westdeutsches Tumorzentrum, Innere Klinik und Poliklinik
45147 Essen
GermanyNoch nicht rekrutierend» Google-Maps
Universitätsklinikum Würzburg, Comprehensive Cancer Center
97078 Würzburg
GermanyNoch nicht rekrutierend» Google-Maps
Hospital Universitari Vall d'Hebron, Institute of Oncology
08035 Barcelona
SpainNoch nicht rekrutierend» Google-Maps
START Madrid, Hospital Universitario HM Sanchinarro
28050 Madrid
SpainRekrutierend» Google-Maps
Clinica Universidad de Navarra, Unidad Central de Ensayos Clinicos
31008 Pamplona
SpainRekrutierend» Google-Maps
University Hospital Zurich, Department of Dermatology
9091 Zurich
SwitzerlandNoch nicht rekrutierend» Google-Maps
Alle anzeigen


Brief Summary:

Part A will be a dose escalation study of IV CTL002 (a monoclonal antibody neutralizing

GDF-15) as monotherapy and in combination with an approved checkpoint inhibitor (CPI) in

patients with advanced solid tumors. Part B will be a cohort expansion into up to five solid

tumor indications.


Main Inclusion Criteria:

- Signed and dated informed consent, and able to comply with the study procedures and

any locally required authorization.

- Male or female aged ≥ 18 years.

- Relapsed/refractory patients with histologically or cytologically confirmed diagnosis

of advanced-stage or recurrent cancer

- Progressed on/relapsed after at least one prior anti-PD-1/PD-L1 treatment

- Biopsy-accessible tumor lesions and willing to undergo triple sequential tumor biopsy

(Part A).

- At least 1 radiologically measurable lesion per RECIST V1.1/imRECIST (Part B).

- Eastern Cooperative Oncology Group (ECOG) performance status 0-1.

- Life expectancy > 3 months as assessed by the Investigator.

- Adequate organ function (bone marrow, hepatic, renal function and coagulation).

Main Exclusion Criteria:

- Pregnant or breastfeeding.

- Any tumor-directed therapy within 21 days before study treatment.

- Treatment with investigational agent within 21 days before study treatment.

- Radiotherapy within 14 days before study treatment.

- Pre-existing arrhythmia, uncontrolled angina pectoris, uncontrolled heart failure

(NYHA II-IV), any myocardial infarction/coronary event, CNS-ischemic event and any

thromboembolic event at any time < 6 months prior to Screening.

- Left ventricular ejection fraction (LVEF) < 50% measured by echocardiogram or MUGA.

- QTcF > 450 ms for men or > 470 ms for women.

- Any active autoimmune requiring systemic immunosuppressive treatments. .

- Any history of non-infectious pneumonitis < 6 months prior to Screening.

- Any active inflammatory bowel disease such as Crohn's disease or ulcerative colitis

which are generally excluded or active autoimmunthyroiditis present < 6 months prior

to Screening.

- History of CNS disease such as stroke, seizure, encephalitis, or multiple sclerosis (<

6 months prior to Screening).


Primary outcome:

1. Adverse Events (Parts A & B) (Time Frame - min. 2 months):
Incidence of treatment emergent adverse events in monotherapy and/or combination therapy

2. Determination of DLT and MTD (Part A) (Time Frame - 28 days):
Assessment of toxicities in monotherapy and/or combination therapy per dose level

3. Evaluation of clinical efficacy according RECIST (Part B) (Time Frame - min. 6 weeks):
RECIST is measured every 6-8 weeks treatment

Secondary outcome:

1. Cmax following the first dose of CTL-002 (Part A & B) (Time Frame - 1 day):
PK parameter from serum CTL-002 levels

2. AUC following the first dose of CTL-002 (Part A & B) (Time Frame - 14 days):
PK parameter from serum CTL-002 levels

3. Half-life of CTL-002 (Part A & B) (Time Frame - min. 6 weeks):
PK parameter from serum CTL-002 levels

4. Evaluation of treatment-emergent cytokine/chemokine concentrations (including TNF-a, IFN-g, IL-2, CXCL-9 and CXCL-10) (Part A & B) (Time Frame - min. 6 weeks):
Measurement of concentration in peripheral blood

5. Evaluation of clinical efficacy according RECIST (Part A) (Time Frame - min. 6 weeks):
RECIST is measured every 6-8 weeks during treatment

6. Evaluation of appetite (Time Frame - min. 6 weeks):
Assessment of appetite via quality of life questionnaire

7. Assessment of Body-Mass-Index (BMI) (kg/m2) (Time Frame - min. 6 weeks):
Calculation of BMI in kg/m2 by combining measurement of body weight in kg and body height in cm

8. Assessment of lumbar vertebra skeletal muscle index (L3SMI) (cm2/m2) (Time Frame - min. 6 weeks):
Combining measurement of L3 vertebra skeletal muscle mass via computed tomography (CT) in cm2 and patient height (squared) in m2


  • Experimental: Part A: CTL-002 Monotherapy + Checkpoint Inhibitor Combination Dose Escalation
    Up to five dose levels with CTL-002 administered as IV monotherapy and in combination with an checkpoint inhibitor
  • Experimental: Part B: CTL-002 Monotherapy + Checkpoint Inhibitor combination
    Up to 2 dose levels with CTL-002 in Part B (expansion)

Geprüfte Regime

  • CTL-002:
    monoclonal antibody


Das könnte Sie auch interessieren
Kehlkopfentfernung – und wie geht es weiter?
© Sebastian Kaulitzki /

Nicht mehr mit der eigenen Stimme sprechen zu können, ist für gesunde Menschen schwer vorstellbar. Wenn jedoch der Kehlkopf infolge einer Tumorerkrankung entfernt werden muss, wird das schnell zur Realität. Simone Kornburger, Case Managerin der Klinik und Poliklinik für Hals-Nasen-Ohren-Heilkunde des Universitätsklinikums Regensburg (UKR), hat einen interdisziplinären Patientenleitfaden entwickelt, der die...